首页> 外文期刊>American journal of rhinology & allergy >Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.
【24h】

Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.

机译:奥洛他定0.6%鼻喷雾剂可预防重度血管舒缩性鼻炎患者的血管舒缩性发作。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Vasomotor rhinitis (VMR) is a hypersensitivity syndrome with heightened reactivity to environmental triggers. METHODS: Twenty-two patients with severe VMR were treated nasally with either normal saline or 0.6% olopatadine and challenged nasally with a hyperosmolar mannitol solution. RESULTS: Treatment with 0.6% olopatadine resulted in an improvement in instantaneous nasal symptom scores at 5 and 30 minutes (p < 0.01) compared with baseline and at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). There was also an improvement in nasal peak inspiratory flow rate at 30 minutes after hyperosmolar challenge compared with saline-pretreated individuals (p < 0.01). CONCLUSION: In this patient population 0.6% olopatadine appears to be efficacious in symptom reduction in VMR and protects from hyperosmolar challenge.
机译:背景:血管舒缩性鼻炎(VMR)是一种过敏反应综合征,对环境触发物的反应性增强。方法:对22例重度VMR患者进行鼻腔注射生理盐水或0.6%奥洛他定,并用高渗甘露醇溶液鼻腔注射​​。结果:与生理盐水预处理组相比,与基线相比,高渗攻击后30分钟,用0.6%的奥洛他定治疗可使鼻腔瞬时症状评分在基线第5和30分钟时有所改善(p <0.01)和在高渗刺激后30分钟(p <0.01)。与用盐水预处理的个体相比,高渗刺激后30分钟鼻吸气峰值流速也有所改善(p <0.01)。结论:在该患者人群中,0.6%的奥洛他定似乎可有效减轻VMR的症状,并能防止高渗挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号